Ocuphire Pharma - OCUP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.00
  • Forecasted Upside: 666.77 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.13
▲ +0.08 (2.62%)

This chart shows the closing price for OCUP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ocuphire Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCUP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCUP

Analyst Price Target is $24.00
▲ +666.77% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Ocuphire Pharma in the last 3 months. The average price target is $24.00, with a high forecast of $26.00 and a low forecast of $22.00. The average price target represents a 666.77% upside from the last price of $3.13.

This chart shows the closing price for OCUP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Ocuphire Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2022Canaccord Genuity GroupLower Target$29.00 ➝ $22.00Low
5/20/2022HC WainwrightReiterated RatingBuy$26.00Medium
3/25/2022HC WainwrightReiterated RatingBuy$26.00Medium
11/24/2021HC WainwrightInitiated CoverageBuy$26.00High
4/5/2021Alliance Global PartnersInitiated CoverageBuy$25.00High
3/29/2021JonestradingInitiated CoverageBuy$20.00High
3/15/2021Cantor FitzgeraldBoost TargetOverweight ➝ Positive$15.00 ➝ $20.00High
11/19/2020Cantor FitzgeraldInitiated CoverageOverweight$15.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/11/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/10/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/9/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/8/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Ocuphire Pharma logo
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Read More

Today's Range

Now: $3.13
Low: $3.10
High: $3.14

50 Day Range

MA: $2.48
Low: $1.99
High: $3.26

52 Week Range

Now: $3.13
Low: $1.78
High: $4.43

Volume

1,237 shs

Average Volume

496,785 shs

Market Capitalization

$65.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Ocuphire Pharma?

The following equities research analysts have issued reports on Ocuphire Pharma in the last twelve months: Canaccord Genuity Group Inc., and HC Wainwright.
View the latest analyst ratings for OCUP.

What is the current price target for Ocuphire Pharma?

2 Wall Street analysts have set twelve-month price targets for Ocuphire Pharma in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 666.8%. HC Wainwright has the highest price target set, predicting OCUP will reach $26.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $22.00 for Ocuphire Pharma in the next year.
View the latest price targets for OCUP.

What is the current consensus analyst rating for Ocuphire Pharma?

Ocuphire Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCUP will outperform the market and that investors should add to their positions of Ocuphire Pharma.
View the latest ratings for OCUP.

What other companies compete with Ocuphire Pharma?

How do I contact Ocuphire Pharma's investor relations team?

Ocuphire Pharma's physical mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company's listed phone number is (248) 681-9815 and its investor relations email address is [email protected] The official website for Ocuphire Pharma is www.ocuphire.com. Learn More about contacing Ocuphire Pharma investor relations.